Previous 10 | Next 10 |
Thinly traded nano cap Mereo BioPharma Group plc ( MREO +20.3% ) is up on average volume, a scant 21K shares, in response to its announcement that six-month interim data form the open-label arm of its Phase 2b clinical trial, ASTEROID , evaluating setrusumab (BPS-804) in patients with o...
LONDON and REDWOOD CITY, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company” or the “Group,” a clinical stage biopharmaceutical company focused on rare diseases, today announce...
LONDON and REDWOOD CITY, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), a clinical stage biopharmaceutical company focused on rare diseases, today announces the appointment of Richard Francis as Head of Pharmaceutical Development, effective Aug...
Gainers: Capricor Therapeutics (NASDAQ: CAPR ) +148% . Carolina Trust BancShares (NASDAQ: CART ) +30% . SSLJ.com Limited (YGTY) +29% . Chicken Soup for the Soul Entertainment (NASDAQ: CSSE ) +22% . AVROBIO (NASDAQ: AVRO ) +22% . Mereo BioPharma Group (NASDAQ: MREO ) +21% . Amer...
Thinly traded nano cap Mereo BioPharma Group plc ( MREO +31.1% ) is up on almost a 13x surge in volume, albeit on turnover of only 261K shares, in response to its announcement that the FDA is on board with a potential accelerated approval pathway for bispecific antibody navicixizumab for...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN LONDON and REDWOOD CITY, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma...
Gainers: VivoPower International (NASDAQ: VVPR ) +108% . Minerva Neurosciences (NASDAQ: NERV ) +43% . PCM (NASDAQ: PCMI ) +42% . Krystal Biotech (NASDAQ: KRYS ) +30% . NRC Group Holdings (NYSEMKT: NRCG ) +26% . India Globalization Capital (NYSEMKT: IGC ) +21% . Rekor Systems (R...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN LONDON and REDWOOD CITY, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma ...
Mereo BioPharma Group plc (NASDAQ: MREO ) announces positive preliminary data from a Phase 2b dose-ranging study, ASTEROID , evaluating BPS-804 (setrusumab) in patients with Type I, II or IV osteogenesis imperfect a, an inherited disorder also called "brittle bone disease" due to fr...
Clear and encouraging percentage changes over baseline in trabecular volumetric bone mineral density measured at the radius at an early readout Expect topline 12 month data from the blinded arms of study to be available in fourth quarter 2019 A call for analysts and investor...
News, Short Squeeze, Breakout and More Instantly...
Mereo BioPharma Group Company Name:
MREO Stock Symbol:
NASDAQ Market:
LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2024, and prov...
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutica...
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate ...